Aptar Pharma Announces Collaboration With Aceso Therapeutics

ACT-101 is an antisense oligonucleotide (ASO) therapy being developed by Aceso Therapeutics to target disease mechanisms linked to CF.

The programme will be supported by Nanopharm, Aptar Pharma’s specialist inhalation development business. Nanopharm will work on formulation development and device testing for ACT-101.

Read More:Lithuanian-Based Surfshark acquires US data privacy firm Optery

Cystic fibrosis is a rare inherited disease that can cause serious damage to the lungs, digestive system, and other organs. It affects around 100,000 people worldwide.

Nanopharm’s work under the Aptar Pharma and Aceso Therapeutics collaboration supports Aptar Pharma’s broader programme to study how complex biologic medicines interact with its inhalation and nasal delivery systems.

The initiatives highlight Aptar Pharma’s focus on developing next-generation inhaled biologic treatments, from early testing through clinical development.

Gemma Budd, General Manager of Nanopharm, an Aptar Pharma company, said, "Cystic fibrosis remains a devastating disease with significant unmet need. Partnering with Aceso Therapeutics enables us to apply our formulation and inhalation science expertise to an innovative oligonucleotide asset.

Thomas Tran, CEO and Co-Founder of Aceso Therapeutics, said, "By partnering with Nanopharm, Aceso Therapeutics aims to accelerate the development of ACT-101 towards clinical evaluation, exploring its potential through direct delivery to the lung. Nanopharm's proven track record in inhaled and nasal drug product development, combined with the wider scientific depth within Aptar Pharma gives us confidence as we continue to advance our ASO platform.

About Aceso Therapeutics

Founded in 2015, by Thomas Tran, Aceso Therapeutics develops RNA-based treatments for genetic diseases. The company builds on more than a decade of academic research and continues to work with the PhyMedExp laboratory. Aceso uses its proprietary PTGR platform to restore gene expression and aims to develop new RNA therapies for patients who have limited treatment options.

Read More:MACOM’s net income triples to $100.7M as Margins Expand